Actively Recruiting
Phase II Study of Trastuzumab Deruxtecan With or Without Anastrozole for Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Led by Jonsson Comprehensive Cancer Center · Updated on 2025-11-10
88
Participants Needed
9
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating trastuzumab deruxtecan alone or combined with anastrozole for treating patients with early-stage HER2 low, hormone receptor positive breast cancer. This phase II trial aims to find which treatment shows the strongest effect based on the pathologic complete response rate and to assess safety, molecular tumor changes, and quality of life during treatment. Participants are randomly assigned to one of two groups. One group receives trastuzumab deruxtecan intravenously every 21 days for up to six cycles, followed by surgery. The second group receives the same trastuzumab deruxtecan treatment plus daily oral anastrozole during each 21-day cycle, also followed by surgery. After completing treatment, patients have a follow-up visit 21 to 28 days later. During the study, patients undergo various assessments including tumor biopsies, molecular biomarker tests, and quality of life questionnaires. Researchers monitor adverse events from the first treatment cycle through study completion, usually about six months. The main outcome measured is the pathologic complete response rate from baseline to surgery, along with other tumor and biomarker analyses.
CONDITIONS
Brief Title
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Research Team
T
TRIO-US
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here